Pacira BioSciences, Inc.
PCRX evidence brief
What we can confirm
- BioSniper Score:
- 5.4 / 10
- Market Cap:
- $1.02B
- Lead Asset:
- EXPAREL (Approved)
What it means
What to watch
Prepared research question
What matters most for PCRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PCRX
Pacira BioSciences, Inc. (PCRX) is a biopharmaceutical company focused on non-opioid pain management and gene therapy, with commercial products EXPAREL and ZILRETTA and a clinical-stage gene therapy platform (HCAd) led by PCRX-201 for osteoarthritis.
Key risk: Thin net income margin
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 catalysts for Pacira BioSciences, Inc..
Pacira BioSciences, Inc. (PCRX) is a biopharmaceutical company focused on non-opioid pain management and gene therapy, with commercial products EXPAREL and ZILRETTA and a clinical-stage gene therapy platform (HCAd) led by PCRX-201 for osteoarthritis.
- Cash and equivalents of $205.9M, total revenue of $192.4M, net income of $4.7M, and shareholders' equity of $672.0M as of 2026-06-30 [sec].
- Lead gene therapy candidate PCRX-201 (enekinragene inzadenovec) for knee osteoarthritis is in Phase 2 and has received FDA Regenerative Medicine Advanced Therapy (RMAT) and EMA Advanced Therapy Medicinal Products (ATMP) designations [sec_mda · as of 2026-08-04].
- Commercial portfolio includes EXPAREL and ZILRETTA; the iovera° cryoanalgesia device was divested in July 2026 [sec_mda · as of 2026-08-04].
- PCRX-201 Phase 1 data reported in August 2026 showed it was well tolerated with exploratory improvements in pain, stiffness, and function over two years [news · published 2026-08-10].
What works
- Strong cash position of $205.9M as of 2026-06-30 provides financial flexibility for R&D and operations [sec].
- PCRX-201 has received both RMAT (FDA) and ATMP (EMA) designations, which are regulatory programs designed to expedite development and review for therapies targeting significant unmet need [sec_mda · as of 2026-08-04].
- The company has a proprietary high-capacity adenovirus (HCAd) vector platform that enables local administration of genetic medicines, potentially addressing large prevalent diseases [sec_mda · as of 2026-08-04].
- Positive two-year Phase 1 data for PCRX-201 showed sustained clinical results, with Phase 2 enrollment advancing and a commercial-ready manufacturing process confirmed [news · published 2026-08-10].
What to weigh
- Net income was only $4.7M on $192.4M revenue as of 2026-06-30, indicating thin profitability [sec].
- The company faces risks associated with acquisitions, divestitures, manufacturing, supply chain, and global economic conditions including tariffs [sec_mda · as of 2026-08-04].
- PCRX-201 is still in Phase 2 and faces competition from other companies developing osteoarthritis treatments, including Eli Lilly and Novo Nordisk [pipeline].
- The divestiture of iovera° in July 2026 removes a commercial product from the portfolio, narrowing the non-opioid device offering [sec_mda · as of 2026-08-04].
From the filings
Quoted directly from source documents.
PCRX-201 is the lead gene therapy candidate with regulatory designations
“PCRX-201 has received Regenerative Medicine Advanced Therapy, or RMAT, designation from the FDA and Advanced Therapy Medicinal Products, or ATMP, designation from the EMA.”
SEC MD&A · August 4, 2026
Positive Phase 1 data for PCRX-201
“Pacira BioSciences reported positive two-year Phase 1 data for its investigational gene therapy PCRX-201 for moderate-to-severe knee osteoarthritis, showing it was well tolerated with exploratory improvements in pain, stiffness, and function”
News · August 10, 2026
Divestiture of iovera° in July 2026
“In July 2026, we completed the divestiture of iovera°, a handheld cryoanalgesia device”
SEC MD&A · August 4, 2026
Catalyst timeline
- 2031-08-04 · Patent_Expiry · TRIAMCINOLONE ACETONIDE — Patent expiry for NDA208845; may open market to generic competition for this product.
- 2044-07-02 · Patent_Expiry · BUPIVACAINE — Patent expiry for NDA022496; potential long-term impact on product exclusivity.
Risks & what to watch (4)›
Key risks
- Thin net income margin — Net income of $4.7M on $192.4M revenue as of 2026-06-30 suggests low profitability [sec].
- Gene therapy development risk — PCRX-201 is in Phase 2; clinical trial failure or regulatory delays could impact pipeline value [sec_mda · as of 2026-08-04].
- Competitive pressure in OA — PCRX-201 faces competition from Eli Lilly and Novo Nordisk in Phase 3 for osteoarthritis treatments [pipeline].
- Macroeconomic and supply chain risks — Risks include tariffs, global economic conditions, and manufacturing/supply chain disruptions [sec_mda · as of 2026-08-04].
What to watch
- Phase 2 data and enrollment progress for PCRX-201, as positive results could de-risk the gene therapy platform [news · published 2026-08-10].
- Commercial performance of EXPAREL and ZILRETTA, which are key revenue drivers post-iovera° divestiture [sec_mda · as of 2026-08-04].
- Regulatory decisions on sNDAs or MAAs for EXPAREL and ZILRETTA, which could expand market access [sec_mda · as of 2026-08-04].
- Patent expirations for TRIAMCINOLONE ACETONIDE (2031-08-04) and BUPIVACAINE (2044-07-02), which may affect long-term competitive positioning [catalyst].
Sources: News · Pipeline · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run Pacira BioSciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pacira BioSciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.85 · 2% dilution
Lead: Approved
2 candidates
2 upcoming, next in ~1755d
0 buys · 7 sells (180d)
Catalysts
Pipeline
Financials
Short Interest
as of Apr 19, 2026- % of float
- 30.0%
- Days to cover
- 9.8
- Shares short
- 8,059,032
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PCRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. (PCRX) is a biopharmaceutical company focused on non-opioid pain management and gene therapy, with commercial products EXPAREL and ZILRETTA and a clinical-stage gene therapy platform (HCAd) led by PCRX-201 for osteoarthritis.
What is Pacira BioSciences, Inc.'s lead drug candidate?
Pacira BioSciences, Inc.'s most advanced tracked candidate is EXPAREL (Approved) for Postsurgical pain management; local analgesia via infiltration in patients aged six years and older and regional analgesia via interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal block in adults..
What is Pacira BioSciences, Inc.'s next catalyst?
Pacira BioSciences, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA208845" — expected August 4, 2031.
Who is the CEO of Pacira BioSciences, Inc.?
Mr. Frank D. Lee is the chief executive officer of Pacira BioSciences, Inc. (PCRX).
Where is Pacira BioSciences, Inc. headquartered?
Pacira BioSciences, Inc. (PCRX) is headquartered in Brisbane, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.